Adverum Biotechnologies, Inc.

Equities

ADVM

US00773U2078

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
9.19 ^USD	-2.13%		-18.96%	+22.08%

Mar. 21	Adverum Biotechnologies Files $200 Million Mixed Shelf	MT
Mar. 19	RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk	MT

Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 04:11 pm EDT

Adverum Biotechnologies, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 31.51 million compared to USD 43.76 million a year ago. Basic loss per share from continuing operations was USD 3.1 compared to USD 4.4 a year ago.
For the six months, net loss was USD 60.57 million compared to USD 81.67 million a year ago. Basic loss per share from continuing operations was USD 6 compared to USD 8.3 a year ago.

Latest news about Adverum Biotechnologies, Inc.

Adverum Biotechnologies Files $200 Million Mixed Shelf	Mar. 21	MT
RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk	Mar. 19	MT
Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Adverum Biotechnologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors	Feb. 20	CI
Transcript : Adverum Biotechnologies, Inc. - Special Call	Feb. 08
Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD	Feb. 08	CI
4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'	Feb. 05	RE
Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors	Feb. 04	CI
Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee	Jan. 29	CI
Adverum Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors	Nov. 06	CI
Adverum Biotechnologies Announces Three-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023	Nov. 04	CI
Mizuho Starts Adverum Biotechnologies With Buy Rating, Price Target is $2	Nov. 02	MT
Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial	23-09-26	CI
Adverum Biotechnologies Names R. Andrew Ramelmeier Chief Technology Officer	23-08-22	MT
Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer	23-08-21	CI
North American Morning Briefing : Stock Futures -2-	23-08-14	DJ
Sector Update: Health Care Stocks Steady Premarket Friday	23-08-11	MT
Chardan Upgrades Adverum Biotechnologies to Buy From Neutral, Expecting Positive Outcome From Ongoing LUNA Trial, Raises Price Target to $4 From $2	23-08-11	MT
Adverum Biotechnologies Completes Enrollment in Mid-Stage Wet AMD Trial, Narrows Q2 Loss	23-08-10	MT
Adverum Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD	23-08-10	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell Microcap Value Index	23-06-23	CI
Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell Microcap Index	23-06-23	CI

Chart Adverum Biotechnologies, Inc.

Duration

Period

More charts

Company Profile

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.19 USD

Average target price

40 USD

Spread / Average Target

+335.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADVERUM BIOTECHNOLOGIES, INC.	+22.08%	191M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs